Outcomes in patients (pts) with bacillus calmette-guerin (bcg)-unresponsive high-risk (hr) non-muscle-invasive bladder cancer (nmibc) who underwent radical cystectomy (rc) following pembrolizumab (pembro) treatment in keynote-057 cohort a